Q-omics provides the consensus-scored PALM profile across patient tissues and cancer cell-line models. PALM expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PALM is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PALM protein abundance shows 36,844 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where PALM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PALM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PALM survival associations across molecular data types. PALM RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PALM RNA expression–survival associations across cancer types. High PALM expression shows unfavorable associations in MESO, but favorable associations in UVM, KIRC, ACC, LAML and THYM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PALM RNA expression.
This table summarizes PALM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PALM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PALM shows lower tumor expression in KIRC, KICH, BLCA, COAD and LUAD and higher tumor expression in THCA. The KIRC box plot shows higher PALM RNA expression in normal versus tumor tissue (log2 FC = −1.737, t-test p < 0.001).
This table shows molecular features associated with PALM in patient tissues and cancer cell lines. In patient samples, PALM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PALM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SOFT_TISSUE.
